Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors

Aim To compare response assessment according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria in patients diagnosed with malignant solid tumors and who had received cytotoxic chemotherapy to establish the strength of agreement between each criterion. Materials and methods Sixty patients with malignant solid tumors were included in this retrospective study. The baseline and the sequential follow-up fluorine- 18-fluorodeoxyglucose PET/computed tomography (CT) of each patient were evaluated according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria. PET/CT images were used for both metabolic and anatomic evaluation. The concurrent diagnostic CTand MRI images (performed within 1 week of PET/CT) were also utilized when needed. The results were compared using the ?-statistics. Results The response and progression rates according to the WHO criteria were 37 and 38%, respectively. The same ratios were also found for RECIST 1.1 (?=1). The response and progression rates according to the EORTC criteria were 47 and 40%, respectively. When PERCIST criteria were used, one patient with progressive disease was upgraded to stable disease (?=0.976). As we found the same results with WHO and RECIST 1.1 criteria, we used WHO criteria to compare the anatomic and metabolic criteria. When we compared the WHO and EORTC criteria, there was an agreement in 80% of the patients (?=0.711). With WHO and PERCIST criteria, there was an agreement in 81.6% of the patients (?=0.736). Conclusion Significant agreement was detected when the WHO, RECIST 1.1, EORTC, and PERCIST criteria were compared both within as well as between each other. © 2015 Wolters Kluwer Health, Inc. All rights reserved.

Yazar Aras M.
Erdil T.Y.
Dane F.
Gungor S.
Ones T.
Dede F.
Inanir S.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4857
Tek Biçim Adres 10.1097/MNM.0000000000000401
Konu Başlıkları 18F-FDG
PERCIST
PET/CT
RECIST 1.1
WHO
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Nuclear Medicine Communications
Dergi Cilt Bilgisi 37
Dergi Sayısı 1
Sayfalar 9 - 15
Yayın Yılı 2016
Eser Adı
[dc.title]
Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors
Yazar
[dc.contributor.author]
Aras M.
Yazar
[dc.contributor.author]
Erdil T.Y.
Yazar
[dc.contributor.author]
Dane F.
Yazar
[dc.contributor.author]
Gungor S.
Yazar
[dc.contributor.author]
Ones T.
Yazar
[dc.contributor.author]
Dede F.
Yazar
[dc.contributor.author]
Inanir S.
Yayın Yılı
[dc.date.issued]
2016
Yayıncı
[dc.publisher]
Lippincott Williams and Wilkins
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Aim To compare response assessment according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria in patients diagnosed with malignant solid tumors and who had received cytotoxic chemotherapy to establish the strength of agreement between each criterion. Materials and methods Sixty patients with malignant solid tumors were included in this retrospective study. The baseline and the sequential follow-up fluorine- 18-fluorodeoxyglucose PET/computed tomography (CT) of each patient were evaluated according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria. PET/CT images were used for both metabolic and anatomic evaluation. The concurrent diagnostic CTand MRI images (performed within 1 week of PET/CT) were also utilized when needed. The results were compared using the ?-statistics. Results The response and progression rates according to the WHO criteria were 37 and 38%, respectively. The same ratios were also found for RECIST 1.1 (?=1). The response and progression rates according to the EORTC criteria were 47 and 40%, respectively. When PERCIST criteria were used, one patient with progressive disease was upgraded to stable disease (?=0.976). As we found the same results with WHO and RECIST 1.1 criteria, we used WHO criteria to compare the anatomic and metabolic criteria. When we compared the WHO and EORTC criteria, there was an agreement in 80% of the patients (?=0.711). With WHO and PERCIST criteria, there was an agreement in 81.6% of the patients (?=0.736). Conclusion Significant agreement was detected when the WHO, RECIST 1.1, EORTC, and PERCIST criteria were compared both within as well as between each other. © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
18F-FDG
Konu Başlıkları
[dc.subject]
PERCIST
Konu Başlıkları
[dc.subject]
PET/CT
Konu Başlıkları
[dc.subject]
RECIST 1.1
Konu Başlıkları
[dc.subject]
WHO
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0143-3636
İlk Sayfa Sayısı
[dc.identifier.startpage]
9
Son Sayfa Sayısı
[dc.identifier.endpage]
15
Dergi Adı
[dc.relation.journal]
Nuclear Medicine Communications
Dergi Sayısı
[dc.identifier.issue]
1
Dergi Cilt Bilgisi
[dc.identifier.volume]
37
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1097/MNM.0000000000000401
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4857
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
7
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
09 Şubat 2024 07:51
Google Kontrol
Tıklayınız
criteria RECIST PERCIST according agreement patients compared response anatomic patient metabolic disease images respectively within tumors between compare progression malignant results stable ratios upgraded progressive reserved rights Health Kluwer Wolters detected Significant Conclusion concurrent criterion
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms